Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey.

Abstract

Although mexiletine effectively treats myotonia, supply disruptions affected Europe between 2008-2018. MyoPath was a mixed-methods, cross-sectional, market research survey conducted January-June 2018 to evaluate consequences of limited access to/awareness of mexiletine in people with myotonia. Part A: qualitative structured interviews (clinicians; advocates for adult patients); Part B: quantitative online questionnaire completed by people with self-reported history of myotonia. Part A: Interviews (clinicians, n=12; patient advocates, n=5; 12 countries) indicated poor mexiletine awareness among general neurologists. Patients chose between living with myotonia (other treatments were generally unsatisfactory) or importing mexiletine. Part B: Questionnaire respondents, myotonic dystrophy (DM)1, n=213; DM2, n=128; non-dystrophic myotonia (NDM), n=41; other n=8; (11 countries). Of the respondents, 76/390 (20%) people with awareness of/access to mexiletine described profound improvements in myotonia and health-related quality of life following treatment. Respondents with NDM had greatest mexiletine experience (n=28/41). Mexiletine was associated with fewer falls, less muscle stiffness, increased mobility. Treatment interruptions worsened myotonia and were associated with fatigue, pain, dysphagia, breathing difficulty, impaired digestion, poor sleep. However, 36/54 (67%) of currently treated people expressed anxiety about mexiletine's availability: this finding was expected (MyoPath was undertaken before mexiletine's approval in NDM). MyoPath provides the largest European exploration of patients' views regarding impact of mexiletine on myotonia. Anticipated effects of mexiletine differ between people with different myotonic disorders: myotonia is the main symptom in NDM but one of many potential symptoms affecting those with DM. Nevertheless, findings indicate substantial harm caused to people with myotonia when mexiletine awareness/access is limited.

• Authors: Jordi Díaz-Manera, J Andoni Urtizberea, Carina Schey, Anna Kole, Philipp von Gallwitz, Amy Whiting, Douglas Foerster, Alla Zozulya-Weidenfeller
• Journal: Neuromuscular disorders : NMD (Neuromuscul Disord) Vol. 33 Issue 2 Pg. 208-217 (02 2023) ISSN: 1873-2364 [Electronic] England
• PMID: 36706619 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022. Published by Elsevier B.V.

Chemical References

• Mexiletine

Topics

• Adult
• Humans
• Mexiletine (therapeutic use)
• Myotonia (drug therapy, diagnosis)
• Quality of Life
• Cross-Sectional Studies
• Myotonic Dystrophy (drug therapy)
• Surveys and Questionnaires